- Previous Close
3.970 - Open
3.930 - Bid 3.610 x --
- Ask 3.700 x --
- Day's Range
3.490 - 3.930 - 52 Week Range
1.400 - 5.420 - Volume
205,800 - Avg. Volume
182,276 - Market Cap (intraday)
1.56B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-0.460 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People's Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve (TMVR) repair system, and JensRelive, a TMVR transfemoral system to treat patients with severe mitral regurgitation; MicroFlux, a transcatheter device to treat heart failure with pressured ejection fraction; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it is involved in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
www.jenscare.comRecent News: 9877.HK
View MorePerformance Overview: 9877.HK
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9877.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9877.HK
View MoreValuation Measures
Market Cap
1.66B
Enterprise Value
1.08B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.19%
Return on Equity (ttm)
-17.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-177.51M
Diluted EPS (ttm)
-0.460
Balance Sheet and Cash Flow
Total Cash (mrq)
605.99M
Total Debt/Equity (mrq)
7.03%
Levered Free Cash Flow (ttm)
--